Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 7 of the 51 sources its claims cite were checked for support.
Abstract
Tuberous sclerosis is a single-gene disorder caused by heterozygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) gene and is frequently associated with mental retardation, autism and epilepsy. Even individuals with tuberous sclerosis and a normal intelligence quotient (approximately 50%) are commonly affected with specific neuropsychological problems, including long-term and working memory deficits. Here we report that mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2(+/-) mice) show deficits in learning and memory. Cognitive deficits in Tsc2(+/-) mice emerged in the absence of neuropathology and seizures, demonstrating that other disease mechanisms are involved. We show that hyperactive hippocampal mammalian target of rapamycin (mTOR) signaling led to abnormal long-term potentiation in the CA1 region of the hippocampus and consequently to deficits in hippocampal-dependent learning. These deficits included impairments in two spatial learning tasks and in contextual discrimination. Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. The results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mTOR antagonists ameliorates cognitive dysfunction in a mouse model of this disorder.
Overview
CoChat Summary
TL;DR
Mice heterozygous for an inactivating *Tsc2* mutation show hippocampal-dependent learning and memory deficits in the absence of neuropathology or seizures, driven by hyperactive mTOR signaling that lowers the threshold for late-phase LTP. Brief rapamycin treatment in adult mice reversed both the synaptic plasticity abnormality and the behavioral deficits.
Key findings
- *Tsc2*+/− mice were impaired on three hippocampus-dependent tasks: Morris water maze probe trial (genotype × quadrant interaction *F*(3,88) = 4.763, *P* = 0.004; target crossings *F*(1,88) = 4.278, *P* = 0.0415), win-shift eight-arm radial maze across-phase errors (*F*(1,36) = 4.724, *P* = 0.0364), and context discrimination (mutants lacked context specificity). Hippocampus-independent visible-platform water maze and other behaviors (motor skills, anxiety, exploration, social approach) were normal.
- Hippocampal tuberin (Tsc2) abundance was reduced to ~75% of WT with unchanged hamartin (Tsc1), and phosphorylated S6 (Ser235/Ser236) was elevated, indicating disinhibited mTOR signaling.
- An E-LTP induction paradigm (1-s, 100-Hz tetanus) produced stable L-LTP in *Tsc2*+/− slices but decaying LTP in WT slices (measure × genotype interaction *F*(29,406) = 2.436, *P* < 0.0001; last 10 min *P* = 0.0328).
- Rapamycin reversed context discrimination deficits and water maze deficits in mutants (three-way ANOVA quadrant occupancy *F*(6,348) = 2.168, *P* = 0.0456; target crossings *F*(6,348) = 2.908, *P* = 0.0088) and reversed abnormal L-LTP; lovastatin did not rescue spatial learning. In *Tsc1*cc–αCaMKII-Cre mice, rapamycin increased survival to ~70% of Mendelian expectation, reduced brain enlargement (*P* < 0.001), and improved hindlimb clasping and ambulation (*P* < 0.001).
Methods
- Behavioral testing of *Tsc2*+/− mice (C57BL/6NCrl background, 3–6-month-old males and females) and conditional *Tsc1*cc–αCaMKII-Cre mice: hidden-platform Morris water maze (4 trials/day, 5 days, probe trial), win-shift eight-arm radial maze (8 daily sessions, 2-min delay), and context fear conditioning (three 0.75-mA shocks, tested in training vs. novel context).
- Acute hippocampal slice field recordings at Schaffer collateral–CA1 synapses (input-output, paired-pulse facilitation, LTP induced by theta burst or 1-s 100-Hz tetanus, recorded 4 h); western blots of hippocampal tuberin, hamartin, and p-S6.
- Rapamycin administered intraperitoneally (5 or 1 mg/kg daily, 3 h before training; 5 mg/kg for 5 days before fear conditioning), 200 nM in slice perfusate, or 0.2 mg/kg/day subcutaneously from postnatal day 1 in the *Tsc1* study; analyses by ANOVA and *t*-tests, *P* < 0.05 significant, experiments blind to genotype and treatment.
Limitations
- The paper states it is unclear whether rapamycin will reverse cognitive deficits caused by cerebral malformations or infantile spasms, and notes that genetic background may account for differences in social behavior between *Tsc1*+/− and *Tsc2*+/− mice and for variable expressivity of tuberous sclerosis phenotypes.
- Evident from the text: all evidence is from mouse models, so the proposed benefit of mTOR inhibitors for cognitive deficits in humans with tuberous sclerosis remains untested; the conditional *Tsc1*cc–αCaMKII-Cre analyses rest on very small surviving samples (e.g., *n* = 3 untreated and *n* = 4 rapamycin-treated mice for brain weight).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 0 Not valid · 27 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the *Tsc2*+/− mouse model, the *Tsc2* gene is disrupted by insertion of a selection cassette in its second coding exon[8](#R8).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The Methods section 'Generation of mice with a targeted, disrupted Tsc2 gene' / 'Generation of a targeted Tsc2 allele in embryonic stem cells and mice' (p. 1 of that section) states the targeting construct was made by insertion of a neomycin resistance (Neo) selection cassette into the second coding exon of Tsc2, with clones selected using G418 and fialuridine. Passage [3] corroborates the disruption location ('As the gene was disrupted in the second coding exon'). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Here we report that mice with a heterozygous, inactivating mutation in the *Tsc2* gene (*Tsc2*+/− mice)[8](#R8) show deficits in learning and memory.”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Abstract
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The citation follows the identification of the Tsc2+/− mice, while “Here we report” presents the learning-and-memory deficits as the citing authors’ own finding. In “Generation of mice with a targeted, disrupted Tsc2 gene,” the source describes producing mice heterozygous for an inactivated Tsc2 allele. It need not report the behavioral deficits to support this identification citation. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a null mutation of the *Pten* gene caused some of the same phenotypes described for the *Tsc1*cc–αCaMKII-Cre mice”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 4.
What the sources say
- Supportedcites [21] Kwon, C.H., Zhu, X., Zhang, J. & Baker, S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA 100, 12923–12928 (2003). source
The introductory passage (page not provided) reports that neuron-specific Pten deletion caused seizures, premature death, and neuronal hypertrophy. The Results also report seizures and ataxia in adult Pten mutant mice. The comparison with Tsc1 mice is the citing authors’ framing; this source supports the attributed Pten phenotypes. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Brain enlargement was largely due to massive neuronal hypertrophy”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“this treatment reversed the context discrimination deficits of *Tsc2*+/− mice ([Fig. 3a](#F3)).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 2.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
75 more claims
Create a free account to see all 109 claims and to verify the 7 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that tuberous sclerosis complex may be a result of the dysregulation of these processes13,69.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar corrections with late-onset treatment in mice have been reported in tuberous sclerosis80 and spinocerebellar ataxia type 1 (SCA1)81.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“Experimental interventions, working through diverse genetic and pharmacological mechanisms, rescue subsets of behavioral abnormalities in these mouse models (31, 43, 48–52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“Target strategies draw from therapeutics under investigation for other neurodevelopmental disorders and hypotheses emerging from mutations in synaptic genes identified in small numbers of individuals with autism spectrum disorders (43, 49, 52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
In the citing paper
“Ehninger et al. further demonstrated that abnormalities of LTP and deficiencies in hippocampal-dependent learning tasks in Tsc2+/- animals, in which mTOR-signaling is abnormally heightened, can be rescued by the mTOR inhibitor rapamycin.”
From Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops (2016) · cites this paper as Ehninger et al., 2008
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“three-way ANOVA for quadrant occupancy with genotype and treatment as between-subjects factors and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“genotype × treatment × quadrant interaction: *F*(6,348) = 2.168, *P* = 0.0456”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“*n* = 12 mice per genotype; two-way ANOVA for quadrant occupancy with genotype as between-subjects factor and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“genotype × pool quadrant interaction: *F* (3,88) = 4.763, *P* = 0.004”
Citations
Cites
Hippocampus, space, and memory
Olton, D. S., Becker, J. T., & Handelmann, G. E. (1979) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00062713 · Cited by 2,018
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
Self-citationIdentification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667 · cited 1×
“To test the efficacy of rapamycin in modulating other tuberous sclerosis brain phenotypes, we studied a homozygous conditional deletion of Tsc1 in neurons of the postnatal forebrain: floxed Tsc1 mice ( Tsc1 cc”
BackgroundSelf-citationFloresco, S. B., Seamans, J. K., & Phillips, A. G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01880.1997 · Cited by 626 · cited 1×
“, and because the hippocampus can contribute to working memor”
BackgroundRegulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 1×
“Second, Tsc1 −/− hippocampal neurons were shown to have morphological and functional synaptic abnormalitie”
BackgroundSelf-citationSancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D., & van den Ouweland, A. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201402 · Cited by 483
The dorsal hippocampus is essential for context discrimination but not for contextual conditioning.
Frankland, P. W., Cestari, V., Filipkowski, R. K., McDonald, R. J., & Silva, A. J. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.4.863 · Cited by 410 · cited 1×
“Discriminating between similar contexts is known to also depend on hippocampal functio”
BackgroundSelf-citationOnda, H., Lueck, A., Marks, P. W., Warren, H. B., & Kwiatkowski, D. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7319 · Cited by 349
Self-citation
Cited by
Items 501–600 of 860
Neonatal and Infantile Epilepsy: Acquired and Genetic ModelsPreprint
Galanopoulou, A. S., & Moshé, S. L. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022707 · Cited by 26
Hien, A., Molinaro, G., Liu, B., Huber, K. M., & Richter, J. D. (2020) · Molecular Autism · doi:10.1186/s13229-020-00384-9 · Cited by 23
“Elevated mTOR signaling contributes to various behavioral and synaptic plasticity phenotypes in the brains of TSC mice as evidenced by their rescue by treatment with the mTOR inhibitor rapamycin [2, 24].”
BackgroundGuerreiro, S. R., & Maciel, P. (2023) · Cells · doi:10.3390/cells12040538 · Cited by 21
Poopal, A. C., Schroeder, L. M., Horn, P. S., Bassell, G. J., & Groß, C. (2016) · Molecular Autism · doi:10.1186/s13229-015-0066-4 · Cited by 23
Increasing our understanding of human cognition through the study of fragile X syndrome
Cook, D., Nuro, E., & Murai, K. K. (2013) · Developmental Neurobiology · doi:10.1002/dneu.22096 · Cited by 22
“Reduced function of TSC1 and/or TSC2 leads to deficits in glutamatergic signaling, synaptic plasticity, and cognition (von der Brelie et al., 2006; Ehninger et al., 2008; Bateup et al., 2011; Ch evere-Torres et al., 2012a,b).”
BackgroundStochastic Model of Tsc1 Lesions in Mouse Brain
Prabhakar, S., Goto, J., Zuang, X., Sena‐Esteves, M., Bronson, R. T., Brockmann, J., Gianni, D., Wojtkiewicz, G. R., Chen, J. W., Stemmer-Rachamimov, A. O., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064224 · Cited by 20
Self-citationWong, A. M., Wang, H.-S., Schwartz, E., Toh, C., Zimmerman, R. A., Liu, P.-L., Wu, Y.-M., Ng, S., & Wang, J. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3507 · Cited by 20
“tardation and learning problems in mouse models of tuberous sclerosis complex.(40,41) Subgroup analysis of a recent phase I/II”
BackgroundFranz, D. N., & Capal, J. K. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s91248 · Cited by 20
“The neurocognitive deficits in these same mouse models of TSC can be reversed with treatment with mTOR inhibitors.(36) Treatment with the mTOR inhibitor rapamycin in adult mice rescued not only synaptic plasticity but also the behavioral deficits in this animal model.”
BackgroundInfluentialLack of association of rare functional variants in TSC1/TSC2 genes with autism spectrum disorder
Bahl, S., Chiang, C., Beauchamp, R. L., Neale, B. M., Daly, M. J., Gusella, J. F., Talkowski, M. E., & Ramesh, V. (2013) · Molecular Autism · doi:10.1186/2040-2392-4-5 · Cited by 23
“Mice with a heterozygous inactivating mutation in Tsc2 exhibit abnormal hippocampal CA1 long-term potentiation (LTP), and consequently deficits in hippocampal-dependent learning [11].”
Self-citationKong, S. W., Sahin, M., Collins, C. D., Wertz, M. H., Campbell, M. G., Leech, J. D., Krueger, D., Bear, M. F., Kunkel, L. M., & Kohane, I. S. (2014) · Molecular Autism · doi:10.1186/2040-2392-5-16 · Cited by 19
“Inactivating mutation in Tsc2 (Tsc2+/− mice) showed defects in axon guidance [11] and cognitive deficits such as impaired water maze performance [12], and mice with Fmr1-knockout (KO) presented impairments in long-term depression, hyperactivity, anxiety-like, and unusual social behaviors [13].”
BackgroundKelu, J. J., & Hughes, S. M. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2422446122 · Cited by 21
Capal, J. K., Ritter, D. M., Franz, D. N., Griffith, M. S., Currans, K., Kent, B., Bebin, E. M., Northrup, H., Koenig, M. K., Mizuno, T., et al. (2024) · Annals of the Child Neurology Society · doi:10.1002/cns3.20070 · Cited by 21
Wong, H. T., McCartney, D. L., Lewis, J. C., Sampson, J. R., Howe, C. J., & de Vries, P. J. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103154 · Cited by 22
Yefidoff‐Freedman, R., Chen, T., Sahoo, R., Chen, L., Wagner, G., Halperin, J. A., Aktas, B. H., & Chorev, M. (2014) · ChemBioChem · doi:10.1002/cbic.201300723 · Cited by 21
Intact neuronal function in Rheb1 mutant mice: implications for TORC1-based treatments
Goorden, S. M. I., Abs, E., Bruinsma, C. F., Riemslagh, F. W., van Woerden, G. M., & Elgersma, Y. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv087 · Cited by 20
“Whereas modest increases in TORC1 activity already result in learning deficits in human and mice (1,13,17), the effect of decreased TORC1 signaling is less clear.”
BackgroundInfluentialPathophysiology of Epilepsy in Autism Spectrum Disorders
Stafstrom, C. E., Hagerman, P. J., & Pessah, I. N. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.003.0071 · Cited by 20
Morè, L., Lauterborn, J. C., Papaleo, F., & Brambilla, R. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.02.003 · Cited by 21
Patil, V., Guzmán, M. A., Carter, A. N., Rathore, G., Yoshor, D., Curry, D. J., Wilfong, A. A., Agadi, S., Swann, J. W., Adesina, A. M., et al. (2015) · Neuropathology · doi:10.1111/neup.12242 · Cited by 20
Another piece of the autism puzzle
State, M. W. (2010) · Nature Genetics · doi:10.1038/ng0610-478 · Cited by 21
Genetic Activation of mTORC1 Signaling Worsens Neurocognitive Outcome after Traumatic Brain Injury
Rozas, N. S., Redell, J. B., Hill, J. L., McKenna, J. T., Moore, A. N., Gambello, M. J., & Dash, P. K. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2014.3469 · Cited by 21
“However, unlike the deficits reported by Silva and colleagues, we did not detect significant learning and memory dysfunction in Tsc2 as assessed by performance in abbreviated water maze and contextual fear tasks.(28) While the reason for this discrepancy is not known, rats (e.”
Potential therapeutic effect of curcumin, a natural mTOR inhibitor, in tuberous sclerosis complex
Kuo, C.-J., Huang, C.-C. S., Chou, S., Lo, Y., Kao, T., Huang, N., Lin, C. B., Lin, H.-C., Lin, H., & Lee, Y. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.203 · Cited by 18
Wang, Y., Pang, L.-Y., Ma, S., Zhang, M., Liu, L., & Zou, L. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.09.017 · Cited by 19
Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice
Chiang, A. C. A., Fowler, S., Savjani, R. R., Hilsenbeck, S. G., Wallace, C. E., Cirrito, J. R., Das, P., & Jankowsky, J. L. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171484 · Cited by 20
“…learning and contextual discrimination while lowering the threshold for synaptic potentiation; in turn, pharmacologic intervention with rapamycin rescued cognitive behavior and synaptic sensitivity, suggesting that mTOR hyperactivity was also necessary for these phenotypes (Ehninger et al., 2008).”
BackgroundWildonger, J., Jan, L. Y., & Jan, Y. N. (2008) · Genes & Development · doi:10.1101/gad.1724108 · Cited by 23
Kagitani‐Shimono, K., Kato, H., Soeda, F., Iwatani, Y., Mukai, M., Ogawa, K., Tominaga, K., Nabatame, S., & Taniike, M. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103288 · Cited by 18
“Furthermore, cognitive deficits in TSC2+/- mice emerged by hyperactive hippocampal mTOR-signaling, even in the absence of neuropathology and seizures, and mTOR inhibitors rescued synaptic plasticity, behavioral deficits, and social behavior (Ehninger et al., 2008).”
Is tuberous sclerosis complex-associated autism a preventable and treatable disorder?
Curatolo, P., Scheper, M., Gialloreti, L. E., Specchio, N., & Aronica, E. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-023-00762-2 · Cited by 20
Scherrer, B., Prohl, A. K., Taquet, M., Kapur, K., Peters, J. M., Tomas-Fernandez, X., Davis, P. E., Bebin, E. M., Krueger, D. A., Northrup, H., et al. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz233 · Cited by 19
“…mice were found to have aberrant projections of axonal pathways (Nie et al. 2010) and behavioral abnormalities consistent with the autism phenotype including deficits in spatial learning, context discrimination, and impaired mother–pup social interaction (Ehninger et al. 2008; Young et al. 2010).”
BackgroundVasić, V., Jones, M. S. O., Haslinger, D., Knaus, L. S., Schmeißer, M. J., Novarino, G., & Chiocchetti, A. G. (2021) · Genes · doi:10.3390/genes12111746 · Cited by 18
“Although survival rate of either Tsc1 or Tsc2 murine homozygous KO offspring is almost null, surviving pups show brain enlargement and abnormally large neurons, while Tsc2+/− heterozygous mutants show lower thresholds for late long-term potentiation [66,67].”
BackgroundResultFard, Y. A., Sadeghi, E. N., Pajoohesh, Z., Gharehdaghi, Z., Khatibi, D. M., Khosravifar, S., Pishkari, Y., Nozari, S., Hijazi, A., Pakmehr, S., et al. (2024) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32986 · Cited by 16
“For instance, mutations in TSC1/2 and PTEN both result in upregulated mTOR activity, yet the behavioral manifestations differ between the two models (Ehninger et al., 2008; Zhou et al., 2009).”
Carbonell-Roig, J., Aaltonen, A., Wilson, K., Molinari, M., Cartocci, V., McGuirt, A. F., Mosharov, E. V., Kehr, J., Lieberman, O. J., Sulzer, D., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114997 · Cited by 18
Convergent synaptic and circuit substrates underlying autism genetic risks
McGee, A. W., Li, G., Lu, Z., & Qiu, S. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1298-y · Cited by 17
Modulation of autophagy as a therapeutic target for Alzheimer’s disease
Steele, J., Fan, E. Y., Kelahmetaglu, Y., Tian, Y., & Bustos, V. (2013) · Postdoc Journal · doi:10.14304/surya.jpr.v1n2.3 · Cited by 18
“The mTOR pathway has been shown to regulate both synthesis and degradation of proteins; thus it has a crucial role in neuronal pathways and is known to be involved in learning and memory (Tischmeyer et al., 2003, Ehninger et al., 2008).”
BackgroundWallin, D. J., Zamora, T., Alexander, M. L., Ennis, K. M., Tran, P. V., & Georgieff, M. (2017) · Pediatric Research · doi:10.1038/pr.2017.88 · Cited by 16
Lin, R., Learman, L. N., Na, C. H., Renuse, S., Chen, K. T., Chen, P. Y., Lee, G.-H., Xiao, B., Resnick, S. M., Troncoso, J. C., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.10.012 · Cited by 17
Koike-Kumagai, M., Fujimoto, M., & Wataya‐Kaneda, M. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109203 · Cited by 17
Stronger is not always better: Could a bodybuilding dietary supplement lead to ALS?
Manuel, M., & Heckman, C. J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.12.007 · Cited by 16
Foyaca-Sibat, H. (2011) · InTech eBooks · doi:10.5772/1137 · Cited by 16
“A TSC mouse treated with rapamycin, also known as sirolimus, was found to have its learning and memory deficits improved (Ehninger et al., 2008).”
BackgroundFocal cortical dysplasia: Molecular disturbances and clinicopathological classification (Review)
Siedlecka, M., Grajkowska, W., Galus, R., Dembowska-Baginska, B. M., & Jóźwiak, J. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2760 · Cited by 16
McKenna, J., Kapfhamer, D., Kinchen, J. M., Wasek, B. L., Dunworth, M., Stewart, T. M., Bottiglieri, T., Casero, R. A., & Gambello, M. J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy118 · Cited by 18
Ham, A., Chang, A. Y., Li, H., Bain, J., Goldman, J. E., Sulzer, D., Veenstra-VanderWeele, J. M., & Tang, G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02741-z · Cited by 17
“The Cre mediated Atg7 depletion led to autophagy de fi ciency at 5 WK in both Atg 7CKO:Aldh1l1CreER and Atg 7CKO: Cx3cr1CreER mice (Fig.”
Driedger, J. H., Schröter, J., PROTECT-Study Group, Hertzberg, C., Weschke, B., Kaindl, A. M., Lücke, T., Thiels, C., Klotz, K. A., Fazeli, W., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03495-1 · Cited by 15
“In animal models, effects have been demonstrated that suggest a reversibility of neuropsychological symptoms through mTOR inhibitor treatment [17–19].”
D’Amore, A., Sundberg, M., Lin, R., Lubbers, E., Winden, K. D., Yu, L., Gawlińska, K., Gawliński, D., Lopez, S. G., Choe, Y., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02916-2 · Cited by 16
“Previous studies of Tsc1/2 mutant mouse models showed that activated mTOR signaling caused macrocephalic brain growth, neurological abnormalities, and reduced survival [27, 48].”
Bassetti, D., Lombardi, A., Kirischuk, S., & Luhmann, H. J. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa187 · Cited by 18
Czapski, G. A., Babiec, L., Jęśko, H. M., Gąssowska-Dobrowolska, M., Cieślik, M., Matuszewska, M., Frontczak‐Baniewicz, M., Zajdel, K., & Adamczyk, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810058 · Cited by 15
“However, in our analysis, Tsc2+/+ and Tsc2+/− mice presented the same levels of sociability which is consistent with previously published results of the analysis of the same mouse strain [79,81].”
ResultRoy, A., Han, V. Z., Bard, A. M., Wehle, D. T., Smith, S. E. P., Ramirez, J., Kalume, F. K., & Millen, K. J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.772847 · Cited by 16
Russo, A. J. (2015) · Biomarker Insights · doi:10.4137/bmi.s21946 · Cited by 19
Etiology of Autism Spectrum Disorder: A Genomics Perspective
Connolly, J. J., & Hakonarson, H. H. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0501-9 · Cited by 22
Coury, D. L., Swedo, S. E., Thurm, A. E., Miller, D. T., Veenstra-VanderWeele, J. M., Carbone, P. S., & Taylor, J. L. (2014) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2013.12.002 · Cited by 20
“These drugs are now in clinical trials in children and adults with FraX (NCT01357239 and NCT01482143), with some promising initial findings.30 Similarly, in the mouse model of TSC, drugs that block mTor (mammalian target of rapamycin) rescue many features of TSC.61,62 These drugs are already on the market for their im…”
BackgroundBassetti, D., Luhmann, H. J., & Kirischuk, S. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02576-5 · Cited by 15
“1 3 affect basal glutamatergic transmission in rat hippocampus [2, 8, 30].”
BackgroundHow DISC1 Regulates Postnatal Brain Development: Girdin Gets In on the AKT
Porteous, D. J., & Millar, K. (2009) · Neuron · doi:10.1016/j.neuron.2009.09.017 · Cited by 15
“…potent immunosuppressant, so it is unlikely to be appropriate for chronic human use, but interestingly both the synaptic plasticity deficit and the cognitive behavior deficit in a mouse model of tuberous sclerosis were reportedly rescued after brief treatment with rapamycin (Ehninger et al., 2008).”
BackgroundCalcineurin inhibition enhances motor neuron survival following injury
Hui, K. K., Liadis, N., Robertson, J. V., Kanungo, A., & Henderson, J. T. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00715.x · Cited by 20
“17-AAG, a cyclophilin/FKBP/calcineurin-independent inhibitor of Hsp-90 and rapamycin, a FKBP-dependent, calcineurin-independent inhibitor of mammalian target of rapamycin (mTOR), were administered daily to animals following axotomy until the time of killing at doses previously demonstrated to produced neural effects i…”
BackgroundSynaptic Plasticity as a Therapeutic Target in the Treatment of Autism-related Single-gene Disorders
Pignatelli, M., Feligioni, M., Piccinin, S., Molinaro, G., Nicoletti, F., & Nisticò, R. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319360008 · Cited by 14
“These mice display a lower threshold for rapamycin-sensitive late phase LTP (L-LTP), as this form of plasticity can be induced following a single train of HFS that would normally only induce early phase LTP (E-LTP), a transient form of LTP [85].”
BackgroundCambiaghi, M., Magri, L., & Cursi, M. (2015) · Seizure · doi:10.1016/j.seizure.2015.02.015 · Cited by 14
“To reproduce temporally and spatially the development of the neurological alterations typical of tuberous sclerosis complex, different CNSrestricted conditional knockout murine models have been generated, by causing loss of either Tsc1 or Tsc2 in differentiating or differentiated neuronal cells (Tsc1c/c/Syn-Cre+ and T…”
Energy sensors in drug addiction: A potential therapeutic target
López-Gambero, A. J., de Fonseca, F. R., & Suárez, J. (2020) · Addiction Biology · doi:10.1111/adb.12936 · Cited by 14
“Thus, deregulated activation of mTOR by THC and aberrant protein synthesis in the hippocampus may be a key mechanism by which a long-term cognitive deficit occurs.(251,252)”
BackgroundResponse of Subependymal Giant Cell Astrocytoma With Spinal Cord Metastasis to Everolimus
Aguilera, D. G., Flamini, R. J., Mazewski, C., Schniederjan, M., Hayes, L. L., Boydston, W. R., Castellino, R. C., & MacDonald, T. J. (2013) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000005 · Cited by 14
Synaptic Plasticity and Learning in Animal Models of Tuberous Sclerosis Complex
Kirschstein, T. (2012) · Neural Plasticity · doi:10.1155/2012/279834 · Cited by 17
“In conclusion, dominant negative Tsc2 mutant mice showed markedly less impaired learning deficits compared with Tsc2+/− mice [29].”
InfluentialGenetics of Tuberous Sclerosis Complex
Kwiatkowski, D. J. (2010) · Wiley eBooks · doi:10.1002/9783527630073.ch4 · Cited by 15
Self-citationKashii, H., Kasai, S., Sato, A., Hagino, Y., Nishito, Y., Kobayashi, T., Hino, O., Mizuguchi, M., & Ikeda, K. (2023) · Human Genomics · doi:10.1186/s40246-023-00450-2 · Cited by 15
Models of KPTN-related disorder implicate mTOR signalling in cognitive and overgrowth phenotypes
Levitin, M. O., Rawlins, L. E., Sánchez-Andrade, G., Arshad, O. A., Collins, S. C., Sawiak, S. J., Iffland, P. H., Andersson, M. H. L., Bupp, C. P., Cambridge, E. L., et al. (2023) · Brain · doi:10.1093/brain/awad231 · Cited by 14
“The promising treatment outcomes of re-lated mTORopathy mouse models 100,106-108 provide encouraging evidence supporting the aim of effective therapeutic intervention in KRD.”
BackgroundMammadova, D., Vecko, J., Hofmann, M., Schüssler, S. C., Deiters, L., Canda, A., Wieland, A., Gollwitzer, S., Hamer, H. M., & Trollmann, R. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02959-0 · Cited by 15
“While animal studies indicate the positive effects of mTOR inhibitors on neurocognitive abilities [57], these potential effects have yet to be investigated in humans [56, 58].”
Allen, S. J., & Morishita, H. (2024) · Science Advances · doi:10.1126/sciadv.adh3920 · Cited by 15
2-Ethylhexanol induces autism-like neurobehavior and neurodevelopmental disorders in zebrafish
Eghan, K., Lee, S., Yoo, D., & Kim, W. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.137469 · Cited by 14
Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation
Rozas, N. S., Redell, J. B., McKenna, J., Moore, A. N., Gambello, M. J., & Dash, P. K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.039 · Cited by 14
“Rapamycin treatment has been shown to reducemTORC1 activity and enhance survival of these mice [13,39].”
Khamsing, D., Lebrun, S., Fanget, I., Larochette, N., Tourain, C., de Sars, V., Brunstein, M., Oheim, M., Carrel, D., Darchen, F., et al. (2021) · Molecular Brain · doi:10.1186/s13041-021-00820-8 · Cited by 14
Enhanced fear limits behavioral flexibility in Shank2-deficient mice
Yun, M., Kim, E., & Jung, M. W. (2022) · Molecular Autism · doi:10.1186/s13229-022-00518-1 · Cited by 13
“Given that Tsc1 and Tsc2 form a complex for signal transduction and Tcs2 deletion increases anxiety [108], the impairment of Tsc1 mutant mice in the reversal of eyeblink conditioning is in line with our finding that an altered emotional response may limit behavioral flexibility in a mouse model of ASD.”
BackgroundMatthiesen, M., Khlaifia, A., Steininger, C. F. D., Dadabhoy, M., Mumtaz, U., & Arruda-Carvalho, M. (2023) · Molecular Brain · doi:10.1186/s13041-023-01028-8 · Cited by 14
Bruining, H., Swaab, H., de Sonneville, L. M. J., van Rijn, S., van Engeland, H., & Kas, M. J. (2011) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2011.00705.x · Cited by 15
“Recent studies have shown that mutant mice for tuberous sclerosis complex (TSC) and fragile X syndrome (FXS) capture cognitive deficits as observed in human patients (Bolduc et al. 2008; Dolen et al. 2007; Ehninger et al. 2008, 2009; McBride et al. 2005).”
BackgroundIshii, R., Wataya‐Kaneda, M., Canuet, L., Nonomura, N., Nakai, Y., & Takeda, M. (2015) · Neuropsychiatric Electrophysiology · doi:10.1186/s40810-015-0004-x · Cited by 13
“In adult mice with a heterozygous, inactivating mutation in the TSC2 gene, mTOR inhibition emerged in the absence of neuropathology and seizures (Ehninger et al. 2008, 2009).”
BackgroundOlexová, L., Talarovičová, A., Lewis-Evans, B., Borbélyová, V., & Kršková, L. (2012) · Neuroscience Research · doi:10.1016/j.neures.2012.10.004 · Cited by 13
Jones, I., Hägglund, A., Törnqvist, G., Nord, C., Ahlgren, U., & Carlsson, L. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.021972 · Cited by 16
“Our observations corroborate the original Drosophila melanogaster studies in which an enlarged-eye phenotype was generated upon Tsc1 or Tsc2 ablation, and further demonstrate that mTORC1 signalling controls organ size within the nervous system (Anderl et al., 2011; Ehninger et al., 2008; Goto et al., 2011; Ito and Rub…”
BackgroundResultInfluentialOkamoto, S., Prikhodko, O., Piña-Crespo, J., Adame, A., McKercher, S. R., Brill, L. M., Nakanishi, N., Oh, C.-K., Nakamura, T., Masliah, E., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.029 · Cited by 13
“In this regard, we found that Tsc2+/− mice displayed a lack of discrimination between the training context and the novel context in the fear conditioning test, consistent with previous reports (Ehninger et al., 2008).”
BackgroundMethodResultInfluentialSex-Selective Effects on Behavior in a Mouse Model of Tuberous Sclerosis Complex
Saré, R. M., Lemons, A., Figueroa, C., Song, A., Levine, M., & Beebe Smith, C. (2020) · eneuro · doi:10.1523/eneuro.0379-19.2020 · Cited by 11
“Reports that did not account for sex did not find any anxiety-like behavior in Tsc2 heterozygous mice (Ehninger et al., 2008, 2012; Potter et al., 2013; Tang et al., 2014), though Tsc2 dominant negative mice (balanced mix of both sexes) did show a trend toward anxiety-like behavior as measured in…”
BackgroundResultAnimal models of tumour-associated epilepsy
Kirschstein, T., & Köhling, R. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.06.008 · Cited by 14
Panaccione, I., King, R., Molinaro, G., Riozzi, B., Battaglia, G., Nicoletti, F., & Bashir, Z. I. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.010 · Cited by 15
“It is intriguing to note that in a recent study it was reported that rapamycin was able to reverse LTP and memory in adult mice with a constitutively active form of mTOR (Ehninger et al 2008).”
Chauhan, A., Chauhan, V., & Brown, T. (2009) · CRC Press eBooks · doi:10.1201/9781420068870-22 · Cited by 13
“…reversal has recently been reported in mouse models of developmental disorders—Fragile X syndrome (Hayashi et al. 2007), Rett Syndrome (Guy et al. 2007), and tuberous sclerosis (Ehninger et al. 2008), all considered genetic and incurable — through molecular intervention, including in older animals.”
BackgroundPrenatal mTOR Inhibitors in Tuberous Sclerosis Complex: Current Insights and Future Directions
Racioppi, G., Checchi, M. P., Sforza, G., Voci, A., Mazzone, L., Valeriani, M., & Moavero, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216335 · Cited by 12
Dysregulation of Alternative Poly-adenylation as a Potential Player in Autism Spectrum Disorder
Szkop, K. J., Cooke, P. I. C., Humphries, J. A., Kalna, V., Moss, D. S., Schuster, E. F., & Nobeli, I. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00279 · Cited by 12
“…the exploration of behavioral and physiological changes as well as the testing of pharmacological interventions in Fmr1 (Gandhi et al., 2014), Cntnap2 (Peñagarikano et al., 2011) and Tsc2 knock-out mice (Ehninger et al., 2008) (a comprehensive review of such studies is given in (Crawley, 2012)).”
BackgroundAnesthetics disrupt brain development via actions on the mTOR pathway
Xu, J., Kang, E., & Mintz, C. D. (2018) · Communicative & Integrative Biology · doi:10.1080/19420889.2018.1451719 · Cited by 12
Animal models of autism: a perspective from autophagy mechanisms
Dana, H., Tahtasakal, R., & Şener, E. F. (2020) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2020.25 · Cited by 18
“Mice carrying a dominant-negative TSC2 mutation had reduced social interactions and preference for social innovations([80]).”
BackgroundJagadeeswaran, I., Pruitt, A., Gautier, N. M., Crane, K., & Glasscock, E. (2021) · Brain and Behavior · doi:10.1002/brb3.2041 · Cited by 13
“…associated with ASD (including Rett syndrome, FXS, and tuberous sclerosis) show improvement of behavioral deficits, synaptic plasticity, and cognitive measures when treated in adulthood (Ehninger et al., 2008; Guy et al., 2007; Mei et al., 2016; Michalon et al., 2012; Silverman et al., 2012).”
BackgroundCôté, V., Knoth, I. S., Agbogba, K., Vannasing, P., Côté, L., Major, P., Michaud, J. L., Barlaam, F., & Lippé, S. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.03.054 · Cited by 16
Focal Cortical Dysplasia in Childhood Epilepsy
Shaker, T., Bernier, A., & Carmant, L. (2016) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2016.06.007 · Cited by 14
Chen, L., Wu, M., Zhu, F., Kai, J., Dong, J., Wu, X., & Zeng, L. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12607 · Cited by 12
“Long-term potentiation and long-term depression of synaptic transmission, the two main formations of long-term synaptic activity, are widely recognized as the molecular mechanism of learning and memory [39,40].”
BackgroundCognitive impairment in epilepsy patients and its correlations
Arslan, G., & Demir, B. (2022) · Applied Neuropsychology Adult · doi:10.1080/23279095.2022.2133606 · Cited by 11
“Also, studies revealed that rapamycin, an mTOR inhibitor, corrected learning difficulties in mice models in TS (Ehninger et al., 2008).”
Mouse Behavior and Models for Autism Spectrum Disorders
Ricceri, L., Michetti, C., & Scattoni, M. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800109-7.00017-0 · Cited by 17
mTOR Signaling in Epilepsy and Epileptogenesis
Leo, A., Constanti, A., Coppola, A., Citraro, R., Sarro, G. D., & Russo, E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00006-2 · Cited by 12
Forebrain depletion of Rheb GTPase elicits spatial memory deficits in mice
Shahani, N., Huang, W., Varnum, M. M., Page, D. T., & Subramaniam, S. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.006 · Cited by 11
Exons as units of phenotypic impact for truncating mutations in autism
Chiang, A. H., Chang, J., Wang, J., & Vitkup, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00876-3 · Cited by 11
CHI, O. Z., Wu, C., Liu, X., Rah, K. H., Jacinto, E., & Weiss, H. R. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8359-5 · Cited by 11
“using both humans and animal models (de Vries 2010; Ehninger et al. 2008) (Zhou et al.”
Çetin, Ö. E., Bilgüvar, K., Korkmaz, B., Bayri, Y., Bayraklı, F., Arlıer, Z., Ozturk, A. K., Yalçınkaya, C., Tüysüz, B., State, M. W., et al. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33312 · Cited by 17
“In fact intensive investigations of the molecular mechanisms underlying these syndromes have led to exciting and novel hypotheses regarding potential treatments for individuals with developmental delay and social disability [Dolen et al., 2007; Dolen and Bear, 2008; Ehninger et al., 2008].”
BackgroundGąssowska-Dobrowolska, M., Czapski, G. A., Cieślik, M., Zajdel, K., Frontczak-Baniewicz, M., Babiec, L., & Adamczyk, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087303 · Cited by 10
MARK1 regulates dendritic spine morphogenesis and cognitive functions in vivo
Kelly-Castro, E. C., Shear, R., Dindigal, A. H., Bhagwat, M., & Zhang, H. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114752 · Cited by 11
“These results suggest that MARK1 cKO mice do not show any obvious spatial memory deficits despite the impaired spatial learning.”
Shank3 related oligodendrocyte alterations in autism are restored by Erk pathway inhibition
Ma, Y., Bauer, H. F., Bockmann, J., Schön, M., Boeckers, T. M., & Lutz, A.-K. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03333-1 · Cited by 11
Cell Type‐Specific mTORC1 Signaling and Translational Control in Synaptic Plasticity and Memory
Huang, Z., Mahmood, N., Wiebe, S. A., Khoutorsky, A., Lacaille, J., & Sonenberg, N. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70281 · Cited by 11
Intellectual Disabilities and Global Developmental Delay
Pinchefsky, E. F., & Shevell, M. I. (2017) · Springer eBooks · doi:10.1007/978-3-319-57196-6_2 · Cited by 11
Doucet, E., Grychowska, K., Zajdel, P., Bockaert, J., Marin, P., & Bécamel, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810178 · Cited by 13
Liu, Y., MA, L., Jiao, L.-B., Gao, M., Guo, W., Chen, L., PAN, N., & Ma, Y. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4444 · Cited by 11
Molecular mechanisms of autism as a form of synaptic dysfunction
Trifonova, E. A., Khlebodarova, T. M., & Gruntenko, N. E. (2017) · Russian Journal of Genetics Applied Research · doi:10.1134/s2079059717080020 · Cited by 11
“mice treated with rapamycin showed a recovery of long-term potentiation and considerable improvements in behavior and learning ability (Ehninger et al., 2009).”
BackgroundInfluentialDo we have a cure for tuberous sclerosis complex?
Crino, P. B. (2008) · Epilepsy Currents · doi:10.1111/j.1535-7511.2008.00279.x · Cited by 10
Saré, R. M., Huang, T., Burlin, T., Loutaev, I., & Smith, C. B. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14311 · Cited by 10
“Decreased protein synthesis could have important implications for neural plasticity in Tsc2 mice and may be responsible for the behavioral impairments and learning and memory deficits seen in this model (Ehninger et al. 2008).”
Background
Metadata
- Authors
- Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Silva, Alcino J
- Venue
- Nature Medicine
- Published
- 2008-06-22
- Volume
- 14
- Issue
- 8
- Pages
- 843-848
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2664098
- OpenAlex
- W1989779456
- Cited by
- 882
- References
- 30
- Citations by year
- 2026: 22 · 2025: 24 · 2024: 23 · 2023: 28 · 2022: 31 · 2021: 40 · 2020: 48 · 2019: 37 · 2018: 40 · 2017: 46 · 2016: 55 · 2015: 76 · 2014: 61 · 2013: 73 · 2012: 90
- FWCI
- 44.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Autism Speaks (AS1862)
- National Institute of Neurological Disorders and Stroke (R01NS038480, P01NS024279)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- tuberous sclerosis complex, mTOR signaling, hippocampal long-term potentiation, hippocampus-dependent learning, spatial learning deficits, contextual discrimination, cognitive impairment, rapamycin, mTOR inhibitors, synaptic plasticity, autism spectrum disorder, intellectual disability
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Animals, Behavior, Animal, Cognition Disorders, Female, Heterozygote, Hippocampus, Learning, Male, Mice, Inbred C57BL, Protein Kinases, Tuberous Sclerosis, Signal Transduction, Sirolimus, Tumor Suppressor Proteins, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.